Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition

FDA approves Regeneron and Sanofi's Dupixent for allergic fungal sinusitis in patients 6 years and older with prior surgery history.

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...
UC San Diego Today

Airborne Toxins Trigger a Unique Form of Chronic Sinus Disease in Veterans

This image shows a section of sinus tissue with mast cells accumulating in the center (purple). A new study from UC San Diego has found that Veterans with chronic rhinosinusitis from airborne toxins ...
Too Old to Operate

Biologic Strategies for Managing Chronic Rhinosinusitis With Nasal Polyps and Asthma

Patients with chronic rhinosinusitis and nasal polyps may also suffer from asthma, creating challenges for physicians since the two conditions can involve different inflammatory mechanisms. However, ...
Mothership.sg

HK singer Joey Yung washed nose 6-7 times a day due to nasal infection but still had green mucus, thought she would never recover

Hong Kong singer Joey Yung shared that she had recently been battling a nasty bout of rhinitis symptoms. In a video on social media on Feb. 7 documenting her recovery journey, she said she had been ...
Scientific Research Publishing

Fokkens, W.J., Lund, V.J., Hopkins, C., et al. (2020) European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology, 58, 1-464.

ABSTRACT: Introduction: Chronic rhinosinusitis (CRS) is a persistent inflammation of the sinus cavities lasting more than 12 weeks. It is a frequent reason for consultation in ENT (Ear, Nose, and ...
Frontiers

Real-world sinonasal outcomes in patients with primary diffuse chronic rhinosinusitis treated with mepolizumab across polyp phenotypes

Mepolizumab blocks IL-5, targeting eosinophilic type-2 inflammation. Due to existing phenotype driven patient selection, evidence of its effectiveness in primary diffuse CRS and CRS without nasal ...
pulmonologyadvisor

GLP-1 Receptor Agonists Tied to Lower Revision Rate After Functional Endoscopic Sinus Surgery

Patients taking GLP-1 RAs had a significantly reduced incidence of revision FESS vs the non-GLP-1 RA group at 1-year and 5-year follow-up. HealthDay News — Use of glucagon-like peptide-1 receptor ...
TMCnet

ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections

MELBOURNE, Australia, Jan. 29, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral ...